- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00345605
Arginine and Buphenyl in Patients With Argininosuccinic Aciduria (ASA), a Urea Cycle Disorder
A Randomized, Double-Blind, Crossover Study of Sodium Phenylbutyrate and Low-Dose Arginine Compared to High-Dose Arginine Alone on Liver Function, Ureagenesis and Subsequent Nitric Oxide Production in Patients With Argininosuccinic Aciduria
Study Overview
Status
Intervention / Treatment
Detailed Description
The cause of liver damage in people with ASA is unknown. However, because ASA is the only urea cycle disorder that is characterized by both liver damage and elevated levels of argininosuccinic acid, researchers believe that the elevated acid levels cause the liver damage. Common treatments for urea cycle disorders include a low-protein diet and arginine supplementation, which, when combined, help to decrease ammonia levels in the blood. Buphenyl-TM may aid in lowering ammonia and argininosuccinic acid levels. Although Buphenyl-TM has been FDA-approved for use in people with some types of urea cycle disorders, there is little information on the effectiveness of the drug in children with ASA. This study will evaluate whether treatment of ASA patients with Buphenyl-TM in conjunction with lowered doses of arginine improves liver function as measured by short-term assessment of synthetic activity and the use of stable isotope tracers to assess ureagenesis and nitric oxide production.
Initially, participants in this double-blind, placebo-controlled, crossover study will undergo a 3-day washout period during which no Buphenyl-TM will be given. They will then be randomly assigned to one of two groups: either Buphenyl-TM (500 mg/kg/day or 10 grams/m2) and arginine (100 mg/kg/day or 2 grams/m2)), or arginine alone (500 mg/kg/day or 10 grams/m2). Participants will remain on this initial treatment arm for 1 week, at the conclusion of which an assessment of hepatic synthetic function, ureagenesis, and nitric oxide production will be performed. After this assessment, participants will undergo a second 3-day washout and then crossover to the other treatment arm for 1 week. At the end of the 1-week treatment period, a second assessment will be performed. During the washout period before each treatment period, no Buphenyl-TM will be administered, and arginine will be administered at the standard therapeutic dose of 500 mg/kg/day or 10 grams/2.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Has confirmed diagnosis of ASA by amino acid or enzyme assay
- Has a history of adequate compliance to the diet and treatment
- Able to take oral or G-tube medication
- Able to perform 24 hour urine collection
- Agrees to travel to Baylor College of Medicine
- If female, of child bearing potential, and sexually active, agrees to use an acceptable method of birth control
- Greater than 5 years of age
Exclusion Criteria:
- Has a history of congestive heart failure, severe renal insufficiency, or any condition that causes sodium retention or edema
- Currently taking Probenecid, Haloperidol, Valproate or oral corticosteroids
- Pregnant or lactating
- Currently being treated for an acute illness
- Has co-morbid associations causing difficulties in the detection of hyperammonemic episodes, liver damage, or difficulties in the diet compliance
- Has known hypersensitivity to sodium phenylbutyrate
- Has taken any experimental medication within the last 30 days
- Has renal insufficiency with creatinine greater than 1.5 mg/dl at screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HDA
High Dose Arm Wash-out then 7 days of: Arg 500 mg/kg/d or 10 g/m2 BSA Placebo instead of NaPBA |
None will be administered during the washout period; 500 mg/kg/day or 10 grams/m2 will be administered during the first one week treatment period in addition to arginine
Other Names:
Standard therapeutic dose of 500 mg/kg/day or 10 grams/2 will be administered during the washout periods, during the first one week treatment period when receiving arginine plus Buphenyl, 100 mg/kg/day or 2 grams/m2 will be administered, during the second treatment week, when receiving arginine alone, 500 mg/kg/day or 10 grams/m2 will be administered
|
Experimental: LDA
Low Dose Arm Wash-out followed by 7 days of: Arg 100 mg/kg/d or 2 g/m2 BSA NaPBA 500 mg/kg/d or 10 g/m2 BSA |
None will be administered during the washout period; 500 mg/kg/day or 10 grams/m2 will be administered during the first one week treatment period in addition to arginine
Other Names:
Standard therapeutic dose of 500 mg/kg/day or 10 grams/2 will be administered during the washout periods, during the first one week treatment period when receiving arginine plus Buphenyl, 100 mg/kg/day or 2 grams/m2 will be administered, during the second treatment week, when receiving arginine alone, 500 mg/kg/day or 10 grams/m2 will be administered
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measures of Liver Function: AST and ALT
Time Frame: Measured after each 1-week treatment period
|
Plasma aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were measured.
|
Measured after each 1-week treatment period
|
Measures of Liver Function: PT and PTT
Time Frame: Measured after each 1-week treatment period
|
Prothrombin time (PT) and partial thromboplastin time (PTT) were measured PT measures factors I (fibrinogen), II (prothrombin), V, VII, and X, while PTT is a performance indicator of the efficacy of the common coagulation pathways.
|
Measured after each 1-week treatment period
|
Measures of Liver Function: Coagulation Factors
Time Frame: Measured after each 1-week treatment period
|
Plasma levels of coagulation factors I and IX were used as measures of hepatic synthetic function since the treatment duration was short.
|
Measured after each 1-week treatment period
|
Measures of Liver Function: INR
Time Frame: Measured after each 1-week treatment period
|
The result (in seconds) for a prothrombin time performed on a normal individual will vary according to the type of analytical system employed.
This is due to the variations between different batches of manufacturer's tissue factor used in the reagent to perform the test.
The INR was devised to standardize the results.
Each manufacturer assigns an ISI value (International Sensitivity Index) for any tissue factor they manufacture.
The ISI value indicates how a particular batch of tissue factor compares to an international reference tissue factor.
The ISI is usually between 1.0 and 2.0.
The INR is the ratio of a patient's prothrombin time to a normal (control) sample, raised to the power of the ISI value for the analytical system being used.
|
Measured after each 1-week treatment period
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Argininosuccinic Acid Levels
Time Frame: Measured after each 1-week treatment period
|
Measured after each 1-week treatment period
|
Arginine Levels
Time Frame: Measured after each 1-week treatment period
|
Measured after each 1-week treatment period
|
Urea Production Rate
Time Frame: Measured after each 1-week treatment period
|
Measured after each 1-week treatment period
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Brendan Lee, MD, PhD, Baylor College of Medicine
Publications and helpful links
General Publications
- Annet L, Materne R, Danse E, Jamart J, Horsmans Y, Van Beers BE. Hepatic flow parameters measured with MR imaging and Doppler US: correlations with degree of cirrhosis and portal hypertension. Radiology. 2003 Nov;229(2):409-14. doi: 10.1148/radiol.2292021128. Epub 2003 Sep 11.
- Lu LG, Zeng MD, Wan MB, Li CZ, Mao YM, Li JQ, Qiu DK, Cao AP, Ye J, Cai X, Chen CW, Wang JY, Wu SM, Zhu JS, Zhou XQ. Grading and staging of hepatic fibrosis, and its relationship with noninvasive diagnostic parameters. World J Gastroenterol. 2003 Nov;9(11):2574-8. doi: 10.3748/wjg.v9.i11.2574.
- Scaglia F, Marini J, Rosenberger J, Henry J, Garlick P, Lee B, Reeds P. Differential utilization of systemic and enteral ammonia for urea synthesis in control subjects and ornithine transcarbamylase deficiency carriers. Am J Clin Nutr. 2003 Oct;78(4):749-55. doi: 10.1093/ajcn/78.4.749.
- Lee B, Yu H, Jahoor F, O'Brien W, Beaudet AL, Reeds P. In vivo urea cycle flux distinguishes and correlates with phenotypic severity in disorders of the urea cycle. Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8021-6. doi: 10.1073/pnas.140082197.
- Brusilow SW, Maestri NE. Urea cycle disorders: diagnosis, pathophysiology, and therapy. Adv Pediatr. 1996;43:127-70. No abstract available.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Genetic Diseases, Inborn
- Brain Diseases, Metabolic
- Brain Diseases, Metabolic, Inborn
- Metabolism, Inborn Errors
- Urea Cycle Disorders, Inborn
- Amino Acid Metabolism, Inborn Errors
- Argininosuccinic Aciduria
- Antineoplastic Agents
- 4-phenylbutyric acid
Other Study ID Numbers
- RDCRN 5102
- U54HD061221 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amino Acid Metabolism, Inborn Errors
-
National Taiwan University HospitalCompletedAromatic L-amino Acid Decarboxylase DeficiencyTaiwan
-
National Human Genome Research Institute (NHGRI)RecruitingInborn Errors of Metabolism | Methylmalonic Acidemia | Organic AcidemiaUnited States
-
ModernaTX, Inc.RecruitingMethylmalonic AcidemiaUnited States, Spain, Canada, Netherlands, France, Australia, United Kingdom
-
LogicBio Therapeutics, IncAlexion Pharmaceuticals, Inc.TerminatedMethylmalonic AcidemiaUnited States
-
ModernaTX, Inc.RecruitingPropionic AcidemiaUnited States, Canada, United Kingdom
-
HemoShear TherapeuticsPrometrika, LLC; AllStripes Research Inc.; Genome MedicalTerminatedPropionic Acidemia | Methylmalonic AcidemiaUnited States, Canada, United Kingdom
-
HemoShear TherapeuticsTerminatedPropionic Acidemia | Methylmalonic AcidemiaUnited States, Saudi Arabia, Australia
-
King Abdullah International Medical Research CenterCompletedPropionic Acidemia | Methylmalonic AcidemiaSaudi Arabia
-
Mendel TuchmanUniversity of Colorado, Denver; Children's Hospital of Philadelphia; University... and other collaboratorsTerminatedPropionic Acidemia | Methylmalonic AcidemiaUnited States
-
ModernaTX, Inc.RecruitingPropionic AcidemiaUnited States, Spain, Netherlands, France, United Kingdom, Australia, Canada, Italy
Clinical Trials on Sodium Phenylbutyrate
-
International Centre for Diarrhoeal Disease Research...Karolinska Institutet; University of Iceland; National Institute of Diseases...CompletedPulmonary TuberculosisBangladesh
-
WestatNational Institute of Neurological Disorders and Stroke (NINDS)TerminatedSpinal Muscular Atrophy Type IUnited States
-
WestatNational Institute of Neurological Disorders and Stroke (NINDS)TerminatedSpinal Muscular Atrophy Type II | Spinal Muscular Atrophy Type IIIUnited States
-
Jerry Vockley, MD, PhDAcer Therapeutics Inc.RecruitingMedium-chain Acyl-CoA Dehydrogenase DeficiencyUnited States
-
US Department of Veterans AffairsMuscular Dystrophy AssociationCompletedAmyotrophic Lateral SclerosisUnited States
-
Horizon Pharma Ireland, Ltd., Dublin IrelandCompletedUrea Cycle DisordersUnited States, Canada
-
University of NottinghamRecruitingObese Non DiabeticUnited Kingdom
-
University of RochesterJohns Hopkins University; Massachusetts General Hospital; University of California... and other collaboratorsCompletedHuntington's DiseaseUnited States
-
University of UtahEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedSpinal Muscular AtrophyUnited States
-
National Cancer Institute (NCI)CompletedLymphoma | Unspecified Adult Solid Tumor, Protocol SpecificUnited States